Abstract
Parkinson’s disease (PD) involves the neurodegeneration of dopaminergic neurons, which is accompanied by neuroinflammation in the substantia nigra (SN). Mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exhibit microglial activation-induced inflammation as well as DA neuronal damage. In this study, treatment with Pogostemon Cabin (PC) prevented the degeneration of the Dopamine (DA) neurons in the substantia nigra (SN). This neuro-protective effect of PC was associated with microglial deactivation and a reduction in CD4+ T cell infiltration. Therefore, the results of this study suggest that PC exerts its neuroprotective function via its anti-inflammatory properties and that PC could be employed as a novel therapeutic agent for PD associated with neuroinflammation and CD4+ T cell infiltration into central nerve system.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
